Global Panitumumab Market Size By End-User, By Application, By Distribution Channel, Geographic Scope And Forecast

Panitumumab Market Size And Forecast

Panitumumab Market size was valued at USD 1.1 Billion in 2023 and is projected to reach USD 1.8 Billion by 2031, growing at a CAGR of 7.1% during the forecasted period 2024 to 2031.

To Get Detailed Analysis: Download Report PDF

Global Panitumumab Market Drivers

The market drivers for the Panitumumab Market can be influenced by various factors. These may include:

• Increasing Prevalence of Colorectal Cancer: Panitumumab is used primarily in the treatment of metastatic colorectal cancer. The rising incidence of colorectal cancer globally, driven by factors like aging populations and lifestyle changes, significantly boosts demand.
• Advancements in Oncology Therapies: Ongoing research and development in cancer treatments, especially targeted therapies like Panitumumab, are expanding its use and driving market growth. New clinical trials and combination therapies also contribute to demand.
• Growing Adoption of Targeted Therapies: As personalized medicine becomes more mainstream, targeted therapies like Panitumumab, which specifically target the epidermal growth factor receptor (EGFR), are gaining traction over traditional chemotherapy, fueling the market.
• Increasing Healthcare Expenditure: Higher investments in healthcare infrastructure, particularly in developing countries, are facilitating better diagnosis and treatment access, which in turn supports the demand for advanced biologic treatments like Panitumumab.
• Expanding Geriatric Population: Colorectal cancer is more prevalent in older populations, and as the global elderly population grows, the need for effective treatments like Panitumumab is expected to rise.
• Regulatory Approvals and Favorable Reimbursement Policies: Governments and healthcare systems are offering more support for innovative cancer therapies, including regulatory approvals and reimbursement policies that make these treatments more accessible.
• Rising Awareness of Cancer Treatment Options: As awareness of advanced cancer treatments increases among patients and healthcare providers, the adoption of targeted therapies like Panitumumab is expected to grow.

Global Panitumumab Market Restraints

Several factors can act as restraints or challenges for the Panitumumab Market. These may include:

• High Treatment Costs: Panitumumab, being a monoclonal antibody used in cancer treatment, is expensive. High costs associated with its development, production, and treatment limit accessibility, particularly in low- and middle-income regions.
• Adverse Side Effects: Panitumumab treatment is associated with significant side effects such as skin toxicity, diarrhea, and electrolyte imbalances. These side effects can reduce its adoption and may lead to discontinuation of therapy.
• Emergence of Biosimilars: The introduction of biosimilar drugs that are more cost-effective poses a threat to the market growth of Panitumumab. These alternatives provide similar efficacy at lower prices, reducing the demand for Panitumumab.
• Stringent Regulatory Approvals: Regulatory hurdles in obtaining approvals for new indications or modifications to existing treatments can slow down market growth. The process of ensuring safety and efficacy through clinical trials is time-consuming and costly.
• Limited Awareness and Availability: In certain regions, awareness regarding Panitumumab’s benefits for treating metastatic colorectal cancer and other cancers may be low. Additionally, its availability can be limited due to supply chain issues or lack of infrastructure.
• Competitive Therapeutic Landscape: Panitumumab faces strong competition from other targeted therapies and immunotherapies, such as cetuximab and bevacizumab, which may offer different benefits in specific patient populations.

Global Panitumumab Market Segmentation Analysis

The Global Panitumumab Market is Segmented on the basis of End-User, Application, Distribution Channel, and Geography.

Panitumumab Market, By Application

• Colorectal Cancer Treatment
• Other Cancer Treatments

The Panitumumab market is primarily segmented by application, with two key subsegments: colorectal cancer treatment and other cancer treatments. Colorectal cancer treatment forms a significant part of the market, as Panitumumab is a targeted monoclonal antibody specifically designed to bind to the epidermal growth factor receptor (EGFR), which is often overexpressed in many colorectal tumors. Patients with wild-type KRAS genes benefit the most from Panitumumab therapy, as its efficacy is linked to the absence of KRAS mutations. This application is essential in the management of metastatic colorectal cancer, facilitating improved survival rates and quality of life for patients through its use in combination with chemotherapy. The shift towards personalized medicine in oncology has further solidified the demand for Panitumumab in this segment.

The second subsegment, other cancer treatments, encompasses the drug’s use against various malignancies beyond colorectal cancer, although it is not as predominant as its use in treating colorectal cancer. This segment includes off-label use cases for cancers such as head and neck squamous cell carcinoma, where EGFR plays a crucial role in tumor growth and progression. Additionally, ongoing clinical trials may further expand the applications of Panitumumab to other types of cancers, driven by research into its mechanisms and the identification of new biomarkers. The growing understanding of cancer biology and the need for targeted therapies continue to drive interest in Panitumumab within this broader application segment. Overall, the Panitumumab market’s segmentation highlights the drug’s role in addressing critical needs in oncology through targeted therapeutic strategies.

Panitumumab Market, By End-User

• Hospitals
• Clinics
• Ambulatory Surgical Centers

The Panitumumab Market can be delineated by end-users into several key segments, primarily focusing on the settings where this monoclonal antibody is administered to patients primarily affected by metastatic colorectal cancer (mCRC) and head and neck cancers. The largest segment, Hospitals, plays a pivotal role as they provide comprehensive healthcare services, including advanced diagnostic and therapeutic capabilities. Within hospitals, Panitumumab is often administered in specialized oncology departments, where a multidisciplinary team evaluates patient eligibility and manages treatment regimens, ensuring adherence to protocols and providing supportive care.

Next, the Clinics sub-segment encompasses outpatient facilities and oncology-specific practices where Panitumumab may be prescribed for cancer treatment, usually involving less complex cases that do not require invasive procedures, thus facilitating a more cost-effective approach for patients and healthcare systems. Finally, Ambulatory Surgical Centers (ASCs) represent a growing sub-segment within the market, providing a facility for outpatient surgeries and treatments. ASCs are becoming increasingly popular for administering therapies like Panitumumab due to their streamlined operations, which can improve patient turnaround times and reduce hospitalization costs. The preference for ASCs is reflective of the wider trend toward outpatient care, optimizing patient convenience while ensuring specialized care. Collectively, these segments illustrate a shift in cancer treatment delivery, highlighting how different healthcare settings are adapting to provide effective and accessible treatment options for patients requiring therapies like Panitumumab.

Panitumumab Market, By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies

The Panitumumab market can be segmented by distribution channel, primarily encompassing Hospital Pharmacies and Online Pharmacies, each playing a crucial role in delivering this targeted therapy for metastatic colorectal cancer. Hospital pharmacies are typically integral parts of healthcare facilities, characterized by their proximity to clinical care, thereby enabling them to provide immediate access to Panitumumab for patients undergoing treatment within the hospital system. These pharmacies often have the advantage of managing complex prescriptions and can provide tailored medication management in collaboration with oncology healthcare professionals, ensuring optimal therapeutic outcomes. On the other hand, Online Pharmacies represent a growing segment within the pharmaceutical landscape, offering an alternative channel for the procurement of Panitumumab.

The increasing digitalization in healthcare enables patients, especially those with chronic conditions, to access medications conveniently without the constraints of geographical barriers. Online pharmacies not only provide home delivery services but also allow for price comparisons and access to a broader range of products, aiding in patient empowerment and adherence to treatment regimens. Additionally, the rise of telemedicine has further enhanced the role of online pharmacies by facilitating remote consultations and prescriptions, which is particularly beneficial for patients in remote locations. Together, these distribution channels—hospital pharmacies and online pharmacies—complement each other, ensuring that Panitumumab is delivered efficiently and effectively to meet the needs of a diverse patient population while navigating the complex healthcare landscape.

Panitumumab Market, By Geography

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• Latin America

The Panitumumab market is segmented by geography, encompassing key regions including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. In North America, particularly the United States, the market is driven by a robust healthcare infrastructure, increasing cancer prevalence, and strong adoption of targeted therapies. The region’s advanced research and development capabilities further enhance market potential.

Europe follows closely, where there are extensive regulatory frameworks and healthcare systems that support oncology treatments. Countries like Germany, France, and the United Kingdom are significant markets due to rising patient awareness and the availability of advanced healthcare technology. In the Asia-Pacific region, the market is experiencing rapid growth fueled by rising incidence of colorectal cancer, improving healthcare access, and increasing investments in healthcare infrastructure. Countries like China and India exhibit high demand due to an expanding middle class and a growing focus on cancer treatment options. The Middle East and Africa market presents unique challenges, including limited healthcare access and lower awareness of targeted therapies. However, growing healthcare investments and increasing disease prevalence offer potential growth opportunities. Finally, Latin America is witnessing a gradual rise in the Panitumumab market, driven by improving healthcare services, rising cancer awareness, and the establishment of better regulatory environments in countries like Brazil and Mexico. Overall, each geographic segment contributes distinct dynamics to the Panitumumab market, influenced by factors such as healthcare policies, prevalence of cancers, and socio-economic conditions.

Key Players

The major players in the Panitumumab Market are:

• Amgen Inc.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Merck KGaA
• Daiichi Sankyo Company, Limited
• Sanofi S.A.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis International AG
• Bayer AG
• Bristol-Myers Squibb Company
• Biogen Inc.
• AbbVie Inc.
• AstraZeneca PLC

Report Scope

Research Methodology of Verified Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team at Verified Market Research.

Reasons to Purchase this Report:

Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support

Customization of the Report

In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.